Rx-360 Remote Audit Best Practice Guide
Rx-360 through our Member Consortium has developed a Version 1.0 Best Practice Guide for Remote Auditing. This initial version will present a foundation on best practices that the Rx-360 membership have utilized and observed as […]
Rx-360 DSCSA Readiness Checklist for Distributors
Wholesale distributors play a pivotal role in safeguarding the integrity of the U.S. pharmaceutical supply chain under the Drug Supply Chain Security Act (DSCSA). The Rx‑360 DSCSA Readiness Checklist for Distributors distills core requirements into […]
Rx-360 Affirms Compliance with the U.S. FDA’s Drug Supply Chain Security Act
Rx-360’s Joint Audit Program has recently reviewed and updated its Good Distribution Practices (GDP) checklist to ensure alignment with the newly implemented and enforced requirements of the U.S. Drug Supply Chain Security Act (DSCSA). These updates reflect evolving FDA enforcement practices and incorporate anonymized, aggregate insights voluntarily shared by Rx-360 members regarding recent DSCSA regulatory assessments, without disclosure of confidential or company-specific inspection materials.
🔍 What is Rx‑360’s GDP checklist?
As part of its Joint Audit Program, Rx-360 offers a consensus-driven GDP checklist used by auditors to assess pharmaceutical manufacturers, suppliers, distributors, third-party logistics providers, and reverse logistics providers. The checklist is developed and regularly refined by industry experts from Rx-360 member companies worldwide, and it incorporates our learnings from the FDA’s recent updated 4003 form, used in recent audit(s). This approach maintains Rx-360’s focus on ensuring consistency, clarity, and alignment with global supply chain best practices and regulatory expectations.
🛠️ Updating for DSCSA alignment
The GDP checklist now integrates key DSCSA requirements, including:
- Verification of Authorized Trading Partners (ATPs): Auditors confirm that trading partners engage only with entities that hold valid federal and state licensure, are appropriately registered where required, and are verified through documented Authorized Trading Partner qualification and oversight processes.
- Product tracing, serialization, and electronic traceability: Auditors review evidence supporting product tracing and serialization compliance, including the availability, accuracy, and retrievability of transaction data, serialization practices, and electronic systems capable of supporting interoperable exchange of traceability information as required under DSCSA.
- Handling suspect or illegitimate products: Auditors examine SOPs and supporting records related to the identification, investigation, quarantine, notification, and disposition of suspect or illegitimate products, ensuring alignment with DSCSA statutory requirements and FDA guidance.
- Records availability and inspection readiness: Audit criteria assess an organization’s ability to promptly produce DSCSA-related records in response to regulatory inquiries, including traceability, verification, and investigation records, consistent with FDA records request and inspection practices.
These enhancements reinforce the checklist’s ability to evaluate both traditional GDP controls and DSCSA compliance in a manner consistent with current FDA enforcement approaches.
✅ Demonstrating audit effectiveness
Rx-360 emphasizes that its Joint Audit Program is designed to identify DSCSA nonconformance in a manner aligned with FDA inspection and enforcement expectations:
- Tailored audit scope: Facility risk assessments explicitly include DSCSA-specific checkpoints, such as ATP qualification, traceability system controls, electronic data exchange capabilities, suspect product handling, and records-request readiness.
- Consortium‑developed tools: The GDP checklist is refined through ongoing collaboration among Rx-360 members and is updated to reflect evolving regulatory guidance and enforcement trends, ensuring DSCSA requirements are embedded within audit protocols.
- CAPA integration: Observed DSCSA nonconformances are documented in audit reports and managed through Rx-360’s Corrective and Preventive Action (CAPA) process, including remediation tracking and re-audit where appropriate.
🤝 Benefits to stakeholders
For manufacturers, suppliers, distributors, regulators, and patients alike, these updates provide:
- Enhanced risk mitigation: Early identification of traceability, ATP qualification, or records-management gaps reduces the risk of counterfeit, diverted, or illegitimate products entering the pharmaceutical supply chain.
- Efficient compliance: Joint audits, including remote and co-sponsored audit models, allow sponsors to leverage shared audit outcomes while maintaining confidentiality and reducing duplicative audit burden.
- Regulatory preparedness: Audits conducted using the updated GDP checklist support readiness for DSCSA compliance and FDA enforcement activities, including electronic traceability expectations and records-based regulatory inquiries.
🎯 The bottom line
With the updated GDP checklist, Rx‑360’s Joint Audit Program now provides:
- A comprehensive GDP audit framework aligned with DSCSA statutory and enforcement expectations
- A structured mechanism to identify and remediate DSCSA nonconformances before regulatory action
- A collaborative, cost-efficient approach for maintaining supply chain integrity and regulatory readiness
By integrating DSCSA requirements into its GDP auditing process, Rx-360 supports audited partners in demonstrating robust distribution practices, effective traceability controls, and inspection-ready compliance programs that protect patients and safeguard the pharmaceutical supply chain, and most importantly, protect patient safety.